Drug Trial Radar · NCT03866369
Multiple Ascending Dose Phase I Study in Order to Define Lanifibranor (IVA337) Supra-thjerapeutic Dose
Last checked: Nov 19, 2026Latest source record: Nov 1, 2019 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
36
Actual
Start
Jan 17, 2019
Primary completion
Aug 27, 2019
Study completion Aug 27, 2019
Sponsor
- Lead sponsor
- Inventiva PharmaIndustry
- Sponsor type
- Industry
- Collaborators
- Parexel
- First posted
- Mar 7, 2019
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- Male only, from 18 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The study will be a double-blind, randomized, placebo-controlled, multiple ascending dose study with lanifibranor. The study will consist of up to 3 cohorts of 12 subjects each; therefore, approximately 36 subjects will be included in this study.
Conditions
- Healthy Subjects
Interventions
MoxifloxacinDrug
Single oral dose at D-8
PlaceboDrug
Single oral dose at D-1
LanifibranorDrug
Single daily oral dose during 14 days
PlaceboDrug
Single daily oral dose during 14 days
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Adverse eventsTime frame: From Baseline up to 15 days
- Number of abnormal Vital signs (blood pressure, pulse) and physical examsTime frame: From Baseline up to 15 days
- Number of abnormal Clinical laboratory tests (chemistry, hematology, urinalysis)Time frame: From Baseline up to 15 days
- Number of abnormal 12-lead digital electrocardiograms parameters (Heart rate, QT/QTc interval, PR interval, QRS interval, RR interval) change from baselineTime frame: From Baseline up to 15 days
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Parexel International GmbH
Berlin, Germany
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.